Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. is registering the resale of 9,103,796 shares of Common Stock pursuant to a post-effective amendment to its Form S-1.
The registration covers (i) 2,346,936 Shares, (ii) 2,346,936 Common Stock Warrant Shares, (iii) 2,079,962 CDI Shares, and (iv) 2,329,962 CDI Warrant Shares. The Company states it will not receive proceeds from resale by the selling stockholders, but may receive up to
This Post-Effective Amendment No. 1 incorporates by reference the Company’s Annual Report on Form 10-K for the fiscal year ended
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported an equity award in the form of 78,740 Restricted Stock Units (RSUs) on March 4, 2026. The RSUs were acquired as a grant at a price of $0.0000 per unit, increasing his direct derivative holdings to 78,740 RSUs.
Each RSU represents a right to receive one CHESS Depositary Interest (CDI), and each CDI represents an interest in one share of Anteris common stock. The RSUs vest in three approximately equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, subject to McDonnell’s continued service through each vesting date.
Anteris Technologies Global Corp. disclosed that its Compensation Committee approved a one-time, discretionary grant of restricted stock units (RSUs) to Chief Financial Officer Matthew McDonnell. The award has a target value of
One-third of the RSUs will vest on each of the first three anniversaries of the grant date, contingent on Mr. McDonnell’s continued employment. The RSUs fully vest earlier if he dies, becomes permanently disabled, or experiences certain terminations in connection with a change in control. Once vested, the RSUs will be settled in CHESS depositary interests of the Company and are described as a special award that does not change his 2026 annual equity target.
Anteris Technologies Global Corp. reported weaker 2025 financial results alongside a strategic update on its DurAVR® transcatheter heart valve program. Revenue from ordinary activities was
The loss from ordinary activities after tax increased to
Anteris Technologies Global Corp. files its annual report describing a development-stage structural heart company focused on the DurAVR® transcatheter heart valve (THV) system for aortic stenosis. DurAVR® combines a single-piece biomimetic valve made from proprietary ADAPT® anti-calcification tissue with the ComASUR® balloon-expandable delivery system.
More than 130 patients have received DurAVR® worldwide through first-in-human, early feasibility and compassionate-use cases, showing favorable hemodynamics and high technical success in small aortic annuli. In 2025, Anteris began a global randomized pivotal Trial comparing DurAVR® to approved TAVR devices, enrolling first patients in Denmark after European approval and securing a staged FDA IDE for the first 200 U.S. patients.
The company targets a growing TAVR market that FMI estimates could reach $9.9 billion for severe aortic stenosis and $2.5 billion for valve-in-valve procedures by 2028, with North America and Europe as core regions. Anteris remains loss-making, relies on single-source suppliers and development partners, holds 47 active patents and 75 pending applications as of December 31, 2025, and faces extensive clinical, regulatory, financing and competitive risks highlighted in its risk factor summary.
Anteris Technologies Global Corp. received an updated ownership filing showing that Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 3,143,154 shares of common stock as of December 31, 2025, representing 7.52% of the outstanding class.
This total includes 612,244 shares that may be acquired within sixty days through warrant exercises. The reporting persons have no sole voting or dispositive power but share voting and dispositive power over all reported shares, which are held in the ordinary course of business and not for the purpose of changing or influencing control.
L1 Capital Pty Ltd, as reporting person, disclosed large indirect purchases of Anteris Technologies Global Corp. common equity through funds it controls and manages. On 01/22/2026, investment funds managed by L1 Capital bought 5,000,000 shares of common stock at $5.75 per share, bringing their indirectly beneficially owned common shares to 13,219,814.
The filing also shows that on 10/28/2025, these funds purchased 1,333,334 CHESS Depository Interests at $4.935 each. Each CHESS Depository Interest represents one underlying share of Anteris common stock and is exchangeable for those shares within 60 days, giving exposure to the same number of underlying common shares.
L1 Capital Pty Ltd has filed an amended Schedule 13G reporting beneficial ownership of 13,219,814 shares of Anteris Technologies Global Corp. common stock, representing 13.6% of the outstanding shares. L1 Capital reports sole voting and dispositive power over these shares.
The position is held through multiple L1-branded funds that L1 Capital controls and manages. The filing amends a prior report that covered 8,219,814 shares and certifies that the securities are held without the purpose or effect of changing or influencing control of Anteris.
Medtronic plc, through its affiliate Covidien Group S.a.r.l., has acquired 15,652,173 shares of Anteris Technologies Global Corp. common stock, representing about 16.2% of the company. The shares were purchased in a private placement at $5.75 per share, for approximately $90 million funded from Covidien’s cash.
As part of the deal, Anteris granted Covidien registration rights for the resale of these shares and entered into an Investor Rights Agreement. Covidien receives a right to participate in certain future issuances, may appoint a non-voting board observer, and is subject to transfer restrictions and a customary standstill through May 22, 2027. The agreement also gives Covidien notice and negotiation rights if Anteris receives certain acquisition proposals.
Medtronic plc, as a 10% owner of Anteris Technologies Global Corp. (AVR), has filed an initial ownership report. The filing shows indirect beneficial ownership of 15,652,173 shares of common stock, which are held through Covidien Group S.a.r.l. rather than directly by Medtronic.